Type Public Website www.amagpharma.com | Products Pharmaceutics Founded 9 November 1981 | |
 | ||
Traded as NASDAQ: AMAG
S&P 600 Component Industry Pharmaceutical Industry Stock price AMAG (NASDAQ) US$ 23.76 +0.46 (+1.97%)27 Feb, 10:33 AM GMT-5 - Disclaimer Headquarters Waltham, Massachusetts, United States | ||
Amag pharmaceuticals ensures business continuity with spanning backup
AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company is a publicly traded company listed on NASDAQ under the symbol "AMAG".
Contents
- Amag pharmaceuticals ensures business continuity with spanning backup
- Operations
- Drug approvals and distribution
- References
In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Operations
AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of US$71,500,000 in 2013.
In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020.
In June 2015 the company acquired Cord Blood Registry for $700 million.
In 2014 AMAG acquired Lumara Health, formerly KV Pharmaceutical Company.
Drug approvals and distribution
The company's research and tests focus on iron deficiency anemia and related intravenous drugs.
In June 2009, the company's main product Ferumoxytol, an oral medication used on adult patients with chronic kidney disease, was approved by US Food and Drug Administration.
In December 2011, Health Canada approved Ferumoxytol, under the brand name Feraheme, for use in treating both dialysis and non-dialysis dependent chronic kidney disease patients, as well as for treatment of adult patients suffering from iron deficiency anemia.
From 2010 to 2014, AMAG had a distribution agreement with Takeda which granted them exclusivity to the Canadian and European Union markets, where the drug is sold under the brand names Feraheme and Rienso, respectively.